Phase 4 N=87 TAP vs Surgical Infiltration of Local Anesthetic in Laparoscopic and Robotic Hysterectomy
Acute Pain
Primary: Total Opioid Use for Pain Control — 20.8; 25.0 mg Morphine equivalents
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060
Atopic Dermatitis
Primary: Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 14 Full Analysis Set — -94; -100 Percent change — p=0.012
N/A N=115 Obtain a Good Blood Glucose Control With the Paradigm Real Time System
Type 1 Diabetes
Primary: Difference in HbA1C From Baseline and 6 Months — -0.57; -0.81 percentage of HbA1C
Phase 3 N=323 Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
Bilateral Nasal Polyposis
Primary: Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms — -0.24; -0.59; -0.68; -0.62 units on a scale
N/A N=177 A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
Liver Diseases · Hepatocellular Cancer · Endstage Liver Disease
Primary: Living Donor Pain Management — 2.62; 2.56; 2.87; 2.67 Scores on Visual Analogue Pain Scale
Phase 2 N=59 Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
Estrogen Receptor-negative Breast Cancer · HER2-negative Breast Cancer · Progesterone Receptor-negative Breast Cancer
Primary: Progression-free Survival (PFS) — 9.1 Months
Phase 2 N=63 Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
Myelofibrosis
Primary: Rate of Non-relapse Mortality at 100 Days Post-transplant — 1; 2; 1 Participants
Phase 3 N=225 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
Rectal Mucinous Adenocarcinoma · Rectal Signet Ring Cell Adenocarcinoma · Recurrent Rectal Carcinoma
Primary: 3-year Overall Survival Rate — 0.965; 0.843; 0.870 proportion of patients — p=0.35
Phase 2 N=70 Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate
Rheumatoid Arthritis
Primary: Change From Baseline in Simple Disease Activity Index (SDAI) Score at Week 8 — 45.15; 44.85; -26.11; -17.38 units on a scale — p=<0.001
N/A N=60 Effects of Electrical Muscle Stimulation on Waist Circumference in Adults
Abdominal Obesity
Primary: Waist Circumference — 87.0; 89.4 cm
Phase 2 N=40 Extended Dosing With Eltrombopag for Severe Aplastic Anemia
Severe Aplastic Anemia (SAA)
Primary: Number of Participants With Drug Response as Defined by Clinically-signficant Hematologic Improvements — 20 Participants
Phase 1 N=12 Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients
Advanced Breast Cancer
Primary: Incidence Rate of DLT Within the First Two Cycles of LDE225 (Sonidegib) in Combination With Docetaxel — 0; 0; 0 Participants
N/A N=2,288 Alive & Thrive Evaluation in Burkina Faso
Breast Feeding · Breast Feeding, Exclusive
Primary: Exclusive Breastfeeding on the Day Preceding the Interview as Assessed by Cross Sectional Survey — 0.933; 0.512 percentage of exclusive breastfeeding
N/A N=80 SmartMouth Advanced Clinical Formula Clinical Research Design Protocol
Gingivitis · Periodontitis
Primary: Gingival Index — -0.22; -0.34; -0.19 units on a scale
N/A N=10 Safety Study of MotifMESH (cPTFE) in Abdominal Surgery
Hernia
Primary: Number of Subjects Who Had an Additional Hernia Occur Following Surgery With Condensed Polytetrafluoroethylene (cPTFE, MotifMESH) Mesh — 0 participants